GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Kitajima, Takahito  (15)
  • 2010-2014  (15)
  • Medicine  (15)
  • 1
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. e22205-e22205
    Abstract: e22205 Background: Peritoneal metastasis shows an extremely poor prognosis in patients with gastric cancer. Clinically, the tumor response to chemotherapeutics depends on anatomical location of metastasis. Metastatic tumor xenografts have been shown to be more resistant to chemotherapy than subcutaneous non-metastatic tumor xenografts in preclinical murine model. We have reported a method of in vivo optical pathology using multiphoton microscopy (MPM) in colorectal liver metastatic tumor xenograft model. Aim: We established a method of time-series in vivo optical pathology of peritoneal metastatic xenografts of gastric cancer using MPM. Then, we imaged and evaluated paclitaxel efficacy in the tumor microenvironment with regard to both tumor cell itself and intravascular change in tumor vessels. Methods: Red fluorescent protein (RFP) expressing human gastric cancer cell line (NUGC4) was inoculated into the peritoneal cavity of green fluorescent protein (GFP) expressing nude mice. Paclitaxel (10 mg/kg) was administered three times a week for more than three weeks. Intravital MPM was performed before and after paclitaxel treatment for the exteriorized peritoneal metastatic lesion in the same living mouse. Results: Four to six weeks later, RFP-NUGC4 cells formed macroscopic peritoneal metastases. Red-colored cancer cells and green-colored surrounding stroma with tumor vessels were clearly imaged at the cellular level (in vivooptical pathology). Their cross-sectional images were obtained from the tissue surface to the area of depth of 200 μm (z-stacks imaging). After paclitaxel treatment, tumor cell fragmentation, condensation, swelling and intracellular vacuoles were observed. Within the tumor vessels, platelet aggregation and platelet adhesion to endothelial cells were observed. Conclusions: In vivo optical pathology using MPM provides histopathological information about three-dimensional tissue microarchitecture without tissue shrinkage by fixation and tissue destruction by microtome-sectioning. Our method may become a powerful tool to evaluate the tumor response to new chemotherapeutics on ‘metastatic site’ in preclinical tumor xenograft model.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2013
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 32, No. 3_suppl ( 2014-01-20), p. 9-9
    Abstract: 9 Background: Angiopoietin-like protein 2 (ANGPTL2) is a secreted glycoprotein with homology to the angiopoietins and is known to act as a causative mediator of chronic inflammation and inflammatory carcinogenesis. Recently, we demonstrated that ANGPTL2 overexpresses in gastric cancer (GC) compared to normal gastric mucosa and high ANGPTL2 is associated with poor prognosis. Therefore, if tumor-derived ANGPTL2 over-secretes systemically, focusing ANGPTL2 in blood is logical to evaluate its ability as a biomarker. Accordingly, we quantified serum ANGPTL2 level and assessed its clinical significance in GC patients. Methods: We screened serum ANGPTL2 levels from 32 GC and 24 normal controls (NC) by ELISA (cohort 1). Next, we validated 194 serum samples from GC and 48 NC (cohort 2). Finally, we examined ANGPL2 expression in matched GC tissues of cohort 2 (n=194) by immunohistochemistry (IHC). The IHC score of ANGPTL2 was determined on the basis of both staining intensity and the percentage of positive cells. Results: In cohort 1,serum ANGPTL2 levels in GC were significantly higher than that in NC (p 〈 0.05). Serum ANGPTL2 differentiated GC from NC with high accuracy (AUC=0.814). Analysis of cohort 2 also indicated that serum ANGPTL2 levels in GC were significantly higher compared to NC (p 〈 0.0001), and increased according to UICC stage progression. In addition, serum ANGPTL2 had a promising AUC (0.831) with high sensitivity (73.0%) and specificity(82.2%) to distinguish GC from NC. High serum ANGPTL2 was significantly associated with lymphatic invasion (p=0.03), vessel invasion (p=0.02), distant metastases (p=0.0002), early recurrence (p=0.004) and poor survival (p=0.01), consequently emerged as an independent predicting recurrence marker (HR=5.06, p=0.0004) and prognostic marker (HR=3.6, p=0.01) in GC. Of interest, ANGPTL2 levels in serum from GC patients closely correlated with IHC scores of cytoplasmic ANGPTL2 at the invasive margin of matched GC tissues (r= 0.16, p=0.02). Conclusions: Serum ANGPTL2 levels, which might be secreted from primary or metastatic site into blood stream, have extremely strong potential as a novel biomarker for diagnosis, predicting recurrence and poor prognosis in GC patients.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2014
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Gastroenterology, Elsevier BV, Vol. 146, No. 5 ( 2014-05), p. S-30-S-31
    Type of Medium: Online Resource
    ISSN: 0016-5085
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2014
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 32, No. 15_suppl ( 2014-05-20), p. e22062-e22062
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2014
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 1167-1167
    Abstract: Background. Trefoil factor 3 (TFF3) is predominantly expressed by goblet cells of the small intestine and colon and its expression is maintained throughout the colon adenoma-carcinoma sequence. Aberrant TFF3 expression in tumor cells has been reported to be involved in tumor progression and unfavorable prognosis of certain human malignancies. In colorectal cancer (CRC), the association between TFF3 expression and tumor progression remains uncertain. Aim. We aimed to investigate the expression of TFF3 in tumor cells using immunohistochemistry and to evaluate its clinical and prognostic values in patients with colorectal cancer (CRC). Materials and methods. Three hundred (n=300) samples of CRC patients were investigated for the expression of TFF3 in tumor cells using standard immunohistochemistry (IHC). The IHC score of TFF3 in tumor cells was determined on the basis of both staining intensity and the percentage of positive cells. The IHC score was dichotomized at the cutoff value predictive of overall survival using a non-parametric receiver operating characteristic analysis. The association between the expression of TFF3 in tumor cells and clinicopathological features was analyzed. Impact of TFF3 expression in tumor cells on overall survival (OS) was also analyzed using univariate and multivariate analyses Results. TFF3 was expressed in all goblet cells of adjacent normal tissue. In adjacent normal colonic crypt, immunoreactive TFF3 protein was localized mainly in the cytoplasm or supranuclear cytoplasm of epithelial cells. Colorectal cancer cells showed an aberrant cytoplasmic TFF3 staining. By use of our dichotomous scoring system, 110 tumors (66%) were low and 190 (34%) were high for TFF3 immunostaining. Decreased expression of TFF3 was significantly associated with larger tumor size ( & lt;0.05), poorly differentiated histology ( & lt;0.01), advanced T stage (T4) (p=0.02), synchronous liver metastasis (p=0.03), and advanced UICC stage (stage 4) (p=0.02). In univariate analysis, decreased tumoral TFF3 was significantly associated with poor prognosis [p=0.02, hazard ratio (HR)=2.13, 95 % CI, 1.15-3.97]. In multivariate analysis, decreased tumoral TFF3 showed a trend toward being an independent prognostic factor for CRC patients [p=0.09, hazard ratio (HR)=1.76, 95 % CI, 0.92-3.37] . Conclusions. Decreased TFF3 expression was associated with colorectal tumor progression. Decreased or lack of TFF3 expression in tumor cells may have a potential prognostic value in CRC patients. Citation Format: Satoru Kondo, Koji Tanaka, Susumu Saigusa, Takahito Kitajima, Tadanobu Shimura, Yuji Toiyama, Yoshinaga Okugawa, Yasuhiro Inoue, Toshimitsu Araki, Keiichi Uchida, Yasuhiko Mohri, Kenichiro Ishii, Masato Kusunoki. Aberrant expression of trefoil factor 3 (TFF3) is associated with tumor progression and an unfavorable prognosis in patients with colorectal cancer . [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1167. doi:10.1158/1538-7445.AM2013-1167
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 1144-1144
    Abstract: Background. Previously, we have reported the association between the expression of tropomyosin-related kinase B (TrkB) in tumor cells and gastric tumor progression, chemoresistance of esophageal cancer, and epithelial-mesenchymal transition in colorectal cancer. In gastric cancer, high tumoral TrkB mRNA level demonstrated to be an independent prognostic factor. Aim. In this study, we investigated the TrkB protein expression in tumor cells using immunohistochemistry, and evaluated its clinical and prognostic significance in patients with human gastric cancer (GC). Materials and methods. Three hundred and twenty (n=320) samples of GC patients were investigated for the TrkB protein expression in tumor cells using a standard immunohistochemistry (IHC). The IHC score of TrkB in tumor cells was determined on the basis of both staining intensity and the percentage of positive cells. The IHC score was dichotomized at the median value as a cutoff value. The association between the TrkB protein expression in tumor cells and clinicopathological features was analyzed. Impact of TrkB protein expression in tumor cells on overall survival (OS) was also analyzed using univariate and multivariate analyses. Results. Immunoreactive TrkB protein was localized in both cytoplasm and nucleus of gastric cancer cells. High cytoplasmic TrkB expression was significantly associated with larger tumor size (p & lt;0.01), well differentiated histology ( & lt;0.01), advanced T stage (p & lt;0.01), lymphovascular invasion (p & lt;0.01), lymph node involvement (p & lt;0.01), synchronous distant metastasis (p & lt;0.01), and advanced UICC stage (p & lt;0.01). Fifty patients (16%) showed a higher TrkB expression in either cytoplasm or nucleus of tumor cells at the tumor invasive front, as compared with the tumor center. In univariate analysis, higher TrkB expression at the tumor invasive front was significantly associated with poor prognosis [hazard ratio (95%): 4.50 (2.78-7.18), p & lt;0.01]. High cytoplasmic TrkB expression did not reach statistical significance. In multivariate analysis, higher TrkB expression at the tumor invasive front retained an independent prognostic factor for GC patients [hazard ratio (95%): 1.77 (1.07-2.88), p=0.03] . Conclusions. Tumoral TrkB expression was associated with tumor progression in human gastric cancer. Increased TrkB at the tumor invasive front was an independent prognostic factor in patients with gastric cancer. Citation Format: Koji Tanaka, Tadanobu Shimura, Susumu Saigusa, Satoru Kondo, Takahito Kitajima, Yuji Toiyama, Yoshinaga Okugawa, Yasuhiro Inoue, Masaki Ohi, Toshimitsu Araki, Keiichi Uchida, Yasuhiko Mohri, Masato Kusunoki. Expression of tropomyosin-related kinase B (TrkB) at the tumor invasive front as an independent prognostic factor in gastric cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1144. doi:10.1158/1538-7445.AM2013-1144
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 2858-2858
    Abstract: Background: Inflammation plays a role in the carcinogenesis of sporadic colorectal cancer (CRC), and this can be supported by several evidences showing that effectiveness of nonsteroidal anti-inflammatory drugs as chemopreventive agents for CRC. Angiopoietin-like protein 2 (ANGPTL2) is known to act as a causative mediator of chronic inflammation and inflammatory carcinogenesis. However, the biological role and clinical significance of ANGPTL2 expression remains poorly understood in human cancer. We investigated the functional roles of ANGPTL2 in vitro and evaluated the clinical significance of ANGPTL2 expression in both primary tumor and matched serum in patients with CRC. Methods: ANGPTL2 gene knockdown by siRNA transfection was performed to evaluate ANGPTL2 function in CRC cancer cell line (sw480). Next, we examined ANGPTL2 expression in CRC tissues (n=194) to evaluate the association between its expression and clinicopathological findings by immunohistochemistry (IHC). Finally, we screened serum ANGPTL2 levels from 32 CRC (16 Stage I and 16 Stage IV) and 24 normal controls (NC), and validated its levels using 194 serum samples from CRC and 48 from NC to evaluate its utility as a biomarker by ELISA. Results: Knockdown of ANGPTL2 resulted in significantly inhibition of cell proliferation, migration, invasion, and resistance to anoikis in vitro. ANGPTL2 overexpressed in CRC tissues compared to normal colonic mucosa and high ANGPTL2 expression was associated with advanced T stage (p & lt;0.01), lymphatic metastasis (p=0.04) and hepatic metastasis (p=0.04) in CRC patients. Next, we screened serum ANGPTL2 levels in CRC patients and NC, revealing that its levels in CRC patients were significantly higher than that in NC (p & lt;0.01), and differentiated CRC patients from NC with high accuracy (AUC=0.837). Validation step also indicated that serum ANGPTL2 levels in CRC patients were significantly higher compared to NC (p & lt;0.0001), had a promising AUC (0.885) with high sensitivity and specificity to distinguish CRC patients from NC. Serum ANGPTL2 levels also discriminated early CRC patients (stage I) from NC (AUC=0.79). High serum ANGPTL2 was significantly associated with tumor progression such as larger tumor size (p=0.03), undifferentiated adenocarcinoma (p=0.03), advanced T stage (p & lt;0.01), peritoneal metastasis (p & lt;0.01) in CRC. Kaplan-Meier curves revealed that high serum ANGPTL2 was significantly associated with poor disease free survival (p=0.01) and overall survival (p=0.03) in CRC. Intriguingly, ANGPTL2 levels in serum from CRC patients closely correlated with IHC scores of ANGPTL2 expression in matched CRC tissues (r=0.14, p=0.03). Conclusion: Our study first reports that overexpression of ANGPTL2 in CRC cells increased malignant potential and metastasis. Serum ANGPTL2, which might be derived from primary CRC tumor, was a novel biomarker for diagnosis and prognosis in patients with CRC. Citation Format: Takahito Kitajima, Yuji Toiyama, Tadanobu Shimura, Shozo Ide, Hiroki Imaoka, Satoru Kondo, Mikio Kawamura, Yoshinaga Okugawa, Aya Kawamoto, Junichiro Hiro, Susumu Saigusa, Masaki Ohi, Koji Tanaka, Yasuhiro Inoue, Yasuhiko Mohri, Sekido Yoshitaka, Masato Kusunoki. Angiopoietin-like protein 2 as a novel serum biomarker for diagnosis and prognosis in patients with colorectal cancer. [abstract] . In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2858. doi:10.1158/1538-7445.AM2014-2858
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 4938-4938
    Abstract: Background: c-MET (hepatocyte growth factor receptor) gene is overexpressed in approximately 20% of gastric cancer. Onartuzumab, a MET-selective humanized one-armed monoclonal antibody, has been studied in metastatic Met-positive non-small cell lung cancer and expected to be introduced to MET-positive gastric cancer. Two-photon laser scanning microscopy (TPLSM) has revolutionized in vivo real-time imaging because of the benefits of higher resolution, increased tissue penetration, and reduced photodamage. We established a method of intravital imaging for intra-abdominal organs using TPLSM with an organ stabilizing system (Japanese Patent No.5268282). Aim: To visualize the binding of fluorescence labeled-antibody to its receptor of cancer cells in peritoneal metastatic xenografts of living mice using a TPLSM. Method: Human gastric cancer cell lines (NUGC4) were inoculated into the peritoneal cavity of green fluorescent protein (GFP) expressing nude mice to make macroscopic peritoneal metastases. In vitro study, the binding of Zenon Alexa Fluor 594 labeled anti-c-MET antibody to viable NUGC4 cells was imaged using fluorescence microscopy. In vivo study, the binding of fluorescence labeled-antibody to viable NUGC4 cells of peritoneal metastatic xenografts was imaged using a TPLSM. Result: Zenon Alexa Fluor 594 labeled anti-c-MET antibody (red) was bound to the surface of viable NUGC4 cells, and clearly visualized under a fluorescence microscopy. Peritoneal metastases with label-free NUGC4 cells (black) and murine stromal cells (green) were imaged under TPLSM in vivo real-time. Fluorescence labeled-antibody could be visualized within tumor vessels of peritoneal metastases after its intravenous administration. Thereafter, label-free NUGC4 cells were identified by the binding of fluorescence labeled- anti-c-MET antibody to c-MET of NUGC4 cells. Conclusion: We could visualize fluorescence labeled-antibody in peritoneal metastases of gastric cancer in living mice using a TPLSM. The binding of fluorescence labeled- anti-c-MET antibody to c-MET of viable NUGC4 cells was clearly imaged at high magnification and high resolution in vivo real-time. It is valuable to develop a method of in vivo optical pathology for therapeutic monoclonal antibodies using MPM on metastatic tumor xenografts. Citation Format: Shozo Ide, Koji Tanaka, Tadanobu Shimura, Masato Okigami, Satoru Kondo, Takahito Kitajima, Hiroki Imaoka, Yoshinaga Okugawa, Susumu Saigusa, Yuji Toiyama, Hiromi Yasuda, Masaki Ohi, Yasuhiro Inoue, Toshimitsu Araki, Keiichi Uchida, Yasuhiko Mohri, Masato Kusunoki. In vivo visualization using two-photon laser scanning microscopy of anti-c-MET antibody in peritoneal metastatic gastric cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4938. doi:10.1158/1538-7445.AM2014-4938
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 1142-1142
    Abstract: Background: Tropomyosin-related receptor kinase B (TrkB) promotes proliferation and invasion related to poor prognoses of various malignancies. TrkB is also involved in resistance to anoikis (a form of detachment-induced apoptosis) and epithelial-to-mesenchymal transition (EMT). Gastric cancer (GC) with mixed histology frequently shows both a well/moderately differentiated (low or intermediate grade) at the surface to the center and a poorly differentiated (high grade) at the invasive front. Dedifferentiation is the progression of cells towards a less differentiated state. Here, we examined the role of TrkB at the invasive front of gastric cancer and its association with tumor cell dedifferentiation. Methods: Immunoreactive TrkB at the invasive front and dedifferentiation, which shows a higher histological grade than that at the surface or center, was evaluated and clarified its clinical and prognostic significance in 320 GC specimens. In vitro study, expression of TrkB, E-cadherin, vimentin, Oct4, and Sox2 at a wound healing edge, which mimics the tumor invasive front, was evaluated in the human GC cell line MKN7. Results: Fifty patients (16%) showed high TrkB expression at the invasive front. Twenty-one patients (6.6%) showed tumor cell dedifferentiation. High TrkB expression at the invasive front and tumor cell dedifferentiation were significantly associated with aggressive phenotypes of GC such as a larger tumor size, depressive macroscopic morphology, lymphovascular invasion, advanced T stage, lymph node involvement, synchronous liver and peritoneal metastasis, and advanced stage. Six patients had high TrkB expression in dedifferentiated GC cells. High TrkB expression at the invasive front was an independent prognostic factor of GC in multivariate analysis (hazard ratio; 1.69, p=0.039). MKN7 cells at the wound healing edge showed increased TrkB, vimentin, Oct4, and Sox2 expression and decreased E-cadherin expression. Tumor cells at the wound edge also showed an increased size and morphological changes in the nucleus or cytoplasm, suggesting that MKN-7 cells at the wound edge may undergo EMT or tumor cell dedifferentiation similar to that of tumor cells at the invasive front of primary tumors. Conclusion: Assessment of immunoreactive TrkB at the tumor invasive front in whole tissue sections provides prognostic information for GC patients. Citation Format: Koji Tanaka, Tadanobu Shimura, Takahito Kitajima, Satoru Kondo, Shozo Ide, Hiroki Imaoka, Yoshinaga Okugawa, Susumu Saigusa, Yuji Toiyama, Yasuhiro Inoue, Tshimitsu Araki, Keiichi Uchida, Yasuhiko Mohri, Masato Kusunoki. Tropomyosin-related receptor kinase B at the invasive front of gastric cancer and tumor cell dedifferentiation. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1142. doi:10.1158/1538-7445.AM2014-1142
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 74, No. 19_Supplement ( 2014-10-01), p. 883-883
    Abstract: Background: Gastric carcinogenesis is regarded as a multistep process with an intestinal metaplasia-dysplasia-carcinoma sequence, which is initiated by Helicobacter pylori infection that causes a chronic active inflammation in the gastric mucosa. Angiopoietin-like protein 2 (ANGPTL2) is known to act as a causative mediator of chronic inflammation and inflammatory carcinogenesis. However, the biological role and clinical significance of ANGPTL2 expression remains poorly understood in human cancer. We investigated the functional role of ANGPTL2 and evaluated the clinical significance of its expression in both primary tumor and matched serum specimens in patients with gastric cancer (GC). Methods: The function of ANGPTL2 in GC was investigated by siRNA using GC cell lines (MKN1 and KATO III). Next, we examined ANGPTL2 expression in GC tissues (n=192) by immunohistochemistry (IHC) to evaluate associations between its expression and various clinicopathological features. Finally, we determined serum ANGPTL2 levels from 32 GC and 23 normal controls (NC), and validated its expression levels using 194 serum samples from GC and 45 from NC to evaluate its utility as a biomarker by ELISA. Results: Knockdown of ANGPTL2 resulted in significant induction of anoikis (p & lt;0.05) and inhibition of cell proliferation (p & lt;0.05), invasion(p & lt;0.05) and migration (p & lt;0.05) in GC cells. ANGPTL2 was overexpressed in GC tissues compared to normal gastric mucosa, and high ANGPTL2 expression was significantly associated lymph node metastasis (p=0.0001), distant metastasis (p=0.01), early recurrence (p=0.003) and poor prognosis (p=0.007) in GC patients. Serum ANGPTL2 levels in GC patients were significantly higher compared to NC (p & lt;0.05), and successfully distinguished GC patients from NC with high accuracy (AUC=0.814). Finally, validation of these results in an independent patient cohort revealed that serum ANGPTL2 levels in GC patients were significantly higher compared to NC (p & lt;0.0001), demonstrated high AUC (0.831) values with 73.0% sensitivity and 82.2% specificity to distinguish GC patients from NC. In addition, serum ANGPTL2 levels also discriminated early GC patients (stage I) from NC (AUC=0.8). High ANGPTL2 in serum rather than in tissues were significantly associated with tumor progression, and consequently emerged as an independent predictor of tumor recurrence (HR=5.05, p=0.0004) and prognosis (HR=3.6, p=0.01) in patients with GC. Of interest, serum ANGPTL2 levels closely correlated with IHC scores in matched GC tissues (r= 0.16, p=0.02). Conclusion: Our study first reports that overexpression of ANGPTL2 in GC cells results in increased malignant potential and metastasis. Serum ANGPTL2 expression emerged as a novel, non-invasive biomarker for the earlier diagnosis, recurrence and prognosis in patients with gastric cancer. Citation Format: Yuji Toiyama, Takahito Kitajima, Tadanobu Shimura, Hiroki Imaoka, Satoru Kondo, Shozo Ide, Masato Okigami, Hiromi Yasuda, Susumu Saigusa, Masaki Ohi, Koji Tanaka, Yasuhiro Inoue, Yasuhiko Mhori, Ajay Goel, Masato Kusunoki. Angiopoietin-like protein 2, a driver of cancer cell metastasis, is a novel serum biomarker for the diagnosis and prognosis in patients with gastric cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 883. doi:10.1158/1538-7445.AM2014-883
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2014
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...